Results 131 to 140 of about 62,107 (294)
British Journal of Haematology, EarlyView.Summary Ruxolitinib remains first‐line standard of care for symptomatic myelofibrosis, but resistance/intolerance develops in most patients. Three Janus kinase inhibitors (JAKis) have entered the post‐ruxolitinib space via distinct pivotal trials. We systematically searched prospective trials evaluating JAKi in refractory adults with myelofibrosis ...
Andrea Duminuco +8 more
wiley +1 more source
Distinct clinical and genetic characteristics of myelodysplastic syndrome in younger patients
British Journal of Haematology, EarlyView.Summary Myelodysplastic neoplasms (formerly myelodysplastic syndromes, MDS) are heterogeneous clonal haematological malignancies that primarily affect the elderly, though a notable proportion of patients are diagnosed at younger ages. We retrospectively analysed 1437 patients diagnosed or treated at Asan Medical Center between 1989 and 2022, comparing ...
Hyunkyung Park +15 more
wiley +1 more source
Congenital disorders of erythropoiesis.
, 1976 Symposium on congenital disorders of erythropoiesis held at the Ciba Foundation, London, 12th-14th March, 1975.
core
Erythropoiesis: insights from a genomic perspective
Erythropoiesis, the process underlying the production of red blood cells, which are essential for oxygen transport, involves the development of hematopoietic stem cells into mature red blood cells.
Hye Ji Cha
core +1 more source
British Journal of Pharmacology, EarlyView.Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley +1 more source
Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy
Cancer Science, EarlyView.This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang +6 more
wiley +1 more source
Erythropoiesis in health and disease: Distinguishing defective and ineffective erythropoiesis
Erythropoiesis is a finely regulated process ensuring continuous red blood cell production to maintain oxygen delivery. Disruptions in this process give rise to defective erythropoiesis, characterized by impaired lineage commitment and progenitor ...
Lizarralde\u2010Iragorri, Maria A. +7 more
core +1 more source
Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs
Clinical Endocrinology, EarlyView.ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams +3 more
wiley +1 more source
Cell Proliferation, EarlyView.The use of FG‐4592 in the process of myeloablation can promote haematopoietic cell apoptosis for more effective myeloablation, maintain the number of RBC and may create a pluripotent microenvironment suitable for donor cells, so as to enable more effective haematopoietic reconstruction of donor cells in vivo.
Guanheng Yang +8 more
wiley +1 more source
Effect of hepatitis C virus infection on erythropoiesis in patients on hemodialysis
, 2013 Chadi Saifan, Elie El-Charabaty, Morton Kleiner, Suzanne El-SayeghDepartment of Medicine, Division of Nephrology, Staten Island University Hospital, Staten Island, NY, USABackground: Erythropoietin is a hormone that regulates erythropoiesis and is mainly
Kleiner M +3 more
core